<DOC>
	<DOCNO>NCT00341523</DOCNO>
	<brief_summary>Esophageal cancer common malignancy poor prognosis . The principal reason poor prognosis tumor asymptomatic go undetected spread beyond esophageal wall unresectable . Significant reduction esophageal cancer mortality require successful strategy diagnose treat case earlier , curable stage disease . A successful early detection program require accurate , patient-acceptable screen test , confirmatory test localize precursor early invasive lesion , one curative therapy acceptable asymptomatic patient . This project include five study design evaluate technique may useful early detection program : 1 . The Cytology Sampling Study estimate compare sensitivity several cytologic sampler identify biopsy-proven dysplasia cancer esophagus . 2 . The Mucosal Staining Study evaluate whether mucosal strain improve endoscopic localization esophageal dysplasia cancer . 3 . The Endoscopic Staging Study evaluate accurately endoscopic technique stage dysplasia early invasive cancer esophagus . 4 . The Endoscopic Therapy Pilot Study evaluate feasibility , safety , acceptability preliminary efficacy endoscopic therapy remove ablate focal high-grade dysplasia early invasive cancer esphagus . 5 . The Chemoregression Study evaluate ability oral chemopreventive agent reduce progression cause regression low-grade squamous dysplasia esophagus . This project carry Linxian , China , county extraordinary rate esophageal cancer correspondingly high prevalence asymptomatic precursor early invasive lesion need study . The project collaborative effort investigator NCI , Cancer Institute Chinese Academy Medical Sciences , several U.S. university .</brief_summary>
	<brief_title>Early Detection Esophageal Cancer</brief_title>
	<detailed_description>Esophageal cancer common malignancy poor prognosis . The principal reason poor prognosis tumor asymptomatic go undetected spread beyond esophageal wall unresectable . Significant reduction esophageal cancer mortality require successful strategy diagnose treat case earlier , curable stage disease . A successful early detection program require accurate , patient-acceptable screen test , confirmatory test localize precursor early invasive lesion , one curative therapy acceptable asymptomatic patient . This project include six study design evaluate technique may useful early detection program : 1 . The Cytology Sampling Study estimate compare sensitivity several cytologic sampler identify biopsy-proven dysplasia cancer esophagus . 2 . The Mucosal Staining Study evaluate whether mucosal stain improve endoscopic localization esophageal dysplasia cancer . 3 . The Endoscopic Staging Study evaluate accurately endoscopic technique stage dysplasia early invasive cancer esophagus . 4 . The Endoscopic Therapy Pilot Study evaluate feasibility , safety , acceptability preliminary efficacy endoscopic therapy remove ablate focal high-grade dysplasia early invasive cancer esophagus . 5 . The Chemoregression Study evaluate ability oral chemopreventive agent reduce progression cause regression low-grade squamous dysplasia esophagus . 6 . The Human Papillomavirus Tissue Study evaluate hypothesis HPV involve pathogenesis esophageal squamous cell carcinoma and/or gastric cardia adenocarcinoma . This project carry Linxian , China , county extraordinary rate esophageal cancer correspondingly high prevalence asymptomatic precursor early invasive lesion need study . The project collaborative effort investigator NCI , Cancer Institute Chinese Academy Medical Sciences .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : Resident Linxian , Henan Province , People 's Republic China . 4069 year age time EGD screening . Visible esophageal lesion mild moderate squamous dysplasia find ( 6 ) EGD screen exam . Confirmation visible index lesion ( 0 ) EGD baseline exam . Willing abstain chronic NSAID use ( define great 3 time per week 2 week ) , exception lowdose aspirin ( less equal 100 mg per day ) , duration study . If subject female childbearing potential ( premenopausal less 2 year postmenopausal surgically sterile ) , must willing use adequate contraception ( abstinence , IUD , birth control pill , spermicidal gel diaphragm condom ) duration study . Appropriate laboratory value within 2 week baseline evaluation : hemoglobin great 11.0 g/dl ; WBC great 3000/mm ( 3 ) ; platelet count great 100,000 ; creatinine le equal 1.5 time upper limit normal ; AST le equal 1.5 time upper limit normal ; Alkaline phosphatase less equal 1.5 upper limit normal ; Pregnancy test negative serum urine ( woman childbearing potential ) . Only patient mild moderate dysplasia base ( 6 ) histology endoscopically visible lesion ( 0 ) evaluation eligible participation inclusion study . To eligible ( 0 ) , subject must confirm , endoscopically visible lesion . EXCLUSION CRITERIA : Diagnosed cancer site , except nonmelanoma skin cancer . Current symptom suggestive upper gastrointestinal tract malignancy , include dysphagia , odynophagia , hematemesis , weight loss great 10 % body weight within past 6 month . Contraindications EGD exam , include hypersensitivity lidocaine iodine , uncontrolled congestive heart failure , unstable angina , bleed disorder severe pulmonary disease . Contraindications use intervention agent , include hypersensitivity selenomethionine , COX2 inhibitor , NSAIDs , salicylates , sulfonamide . Treated peptic ulcer disease within past month prior baseline evaluation . Acute chronic kidney disease , liver disease , asthma . Pregnant nursing infant . Other serious health condition might preclude study completion ( discretion investigator ) . Currently use fluconazole lithium .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 22, 2016</verification_date>
	<keyword>Cytology</keyword>
	<keyword>Endoscopy</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Early Detection</keyword>
	<keyword>Treatment</keyword>
</DOC>